Chemomab Therapeutics Ltd. (CMMB) annual balance sheet — 11-year assets, liabilities & equity history
| Total Current Assets | 13.42M | 16.04M | 20.9M | 41.74M | 62.69M | 11.84M | 18.21M | 10.92M | 1.59M | 4.87M | 3.1M |
| Cash & Short-Term Investments | 10.37M | 14.27M | 19.78M | 39.89M | 61.16M | 11.7M | 17.58M | 7.52M | 1.45M | 4.56M | 2.36M |
| Cash Only | 7.56M | 6.07M | 9.29M | 13.52M | 14.69M | 11.67M | 17.58M | 7.52M | 1.45M | 4.56M | 2.21M |
| Short-Term Investments | 2.8M | 8.2M | 10.49M | 26.37M | 45.98M | 24K | 0 | 0 | 0 | 0 | 151.12K |
| Accounts Receivable | 3.06M | 263K | 289K | 459K | 179K | 74K | 636K | 3.4M | 88K | 139.01K | 129.78K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | -1.35M | 0 | -542 | -77K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 76K | 76K | 77K | 1.35M | 0 | -26.46K | 23K | 0 | 0 | 0 |
| Total Non-Current Assets | 386.99K | 924K | 1.25M | 1.33M | 1.67M | 637K | 1.54M | 1.84M | 498K | 781.05K | 418.14K |
| Property, Plant & Equipment | 176K | 539K | 695K | 594K | 702K | 580K | 1.36M | 385K | 219K | 213.32K | 176.3K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 6.62K | 8.02K | 0 | 14K | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 55K | 4K | 130K | 120K | 0 | 0 | 0 |
| Other Non-Current Assets | 211K | 378.38K | 550.98K | 733K | 894K | 53K | 57K | 1.34M | 279K | 567.73K | 241.84K |
| Total Assets | 13.81M | 16.96M | 22.15M | 43.06M | 64.35M | 12.48M | 19.76M | 12.76M | 2.09M | 5.65M | 3.52M |
| Asset Turnover | - | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -18.58% | -23.42% | -48.56% | -33.08% | 415.81% | -36.85% | 54.81% | 511.45% | -63.06% | 60.7% | - |
| Total Current Liabilities | 1.48M | 3.22M | 4.84M | 6.75M | 2.65M | 1.32M | 4.12M | 2.75M | 2.7M | 2.36M | 1.33M |
| Accounts Payable | 484.99K | 666K | 516K | 1.69M | 1.34M | 93K | 25K | 396K | 160K | 106.53K | 589.56K |
| Days Payables Outstanding | - | 4.56K | 2.82K | 10.66K | 14.33K | 424.32 | 32.37 | 2.19K | 1.15K | 956.82 | 8.2K |
| Short-Term Debt | 0 | 115K | 76K | 0 | 106K | 179K | 391K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 337K | 759K | 747K | 1.56M | -106K | -179K | 3.05M | 1.62M | 2.54M | 2.25M | 743.24K |
| Current Ratio | 9.08x | 4.98x | 4.32x | 6.18x | 23.66x | 9.00x | 4.42x | 3.98x | 0.59x | 2.07x | 2.32x |
| Quick Ratio | 9.08x | 4.98x | 4.32x | 6.18x | 24.16x | 9.00x | 4.42x | 4.00x | 0.59x | 2.07x | 2.32x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 209K | 316K | 91K | 237K | 358K | 725K | 210K | 0 | 0 | 37.78K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 209K | 316K | 91K | 237K | 358K | 108K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 617K | 210K | 0 | 0 | 37.78K |
| Total Liabilities | 1.48M | 3.43M | 5.15M | 6.84M | 2.89M | 1.67M | 4.85M | 2.96M | 2.7M | 2.36M | 1.37M |
| Total Debt | 0 | 324K | 392K | 214K | 343K | 607K | 586K | 0 | 0 | 0 | 0 |
| Net Debt | -7.56M | -5.75M | -8.9M | -13.3M | -14.34M | -11.07M | -16.99M | -7.52M | -1.45M | -4.56M | -2.21M |
| Debt / Equity | - | 0.02x | 0.02x | 0.01x | 0.01x | 0.06x | 0.04x | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -80.83x | -111.34x | -995.50x | -3022.56x | - | -1910.40x | - | -528.82x |
| Total Equity | 12.33M | 13.54M | 17M | 36.22M | 61.47M | 10.8M | 14.91M | 9.8M | -609K | 3.29M | 2.14M |
| Equity Growth % | -8.89% | -20.36% | -53.08% | -41.07% | 469.02% | -27.55% | 52.06% | 1710.02% | -118.49% | 53.52% | - |
| Book Value per Share | 1.93 | 3.02 | 5.79 | 12.73 | 23.70 | 23.29 | 34.63 | 62.09 | -53.98 | 48.48 | 37.68 |
| Total Shareholders' Equity | 12.33M | 13.54M | 17M | 36.22M | 61.47M | 10.8M | 12.37M | 9.8M | -609K | 3.29M | 2.14M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.77M | 1.92M | 1.26M |
| Retained Earnings | -111.62M | -102.62M | -88.68M | -63.82M | -36.17M | -23.7M | -17.74M | -78.31M | -62.88M | -52.7M | -47.46M |
| Treasury Stock | 0 | 0 | 0 | -1.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 872K | 4.44M | 2.22M | 1.32M | 1.07M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying CMMB stock.
As of 2025, Chemomab Therapeutics Ltd. (CMMB) had total assets of $13.8M including $13.4M in current assets.
Chemomab Therapeutics Ltd. (CMMB) carries total debt of $0.0M, offset by $10.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Chemomab Therapeutics Ltd. (CMMB) has total shareholders' equity (book value) of $12.3M ($1.93 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Chemomab Therapeutics Ltd. (CMMB) reported a current ratio of 9.08x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.